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An Update of the Mayo Clinic Cohort of Patients With Adult
Primary Central Nervous System Vasculitis
Description of 163 Patients
Carlo Salvarani, MD, Robert D. Brown Jr, MD, Teresa Christianson, BS, Dylan V. Miller, MD,
Caterina Giannini, MD, John Huston III, and Gene G. Hunder, MD
Abstract: Primary central nervous system vasculitis (PCNSV) is an
uncommon condition in which lesions are limited to vessels of the brain
and spinal cord. Because the clinical manifestations are not specific, the
diagnosis is often difficult, and permanent disability and death are
frequent outcomes. This study is based on a cohort of 163 consecutive
patients with PCNSV who were examined at the Mayo Clinic over a 29-
year period from 1983 to 2011. The aim of the study was to define the
characteristics of these patients, which represents the largest series in
adults reported to date. A total of 105 patients were diagnosed by
angiographic findings and 58 by biopsy results. The patients diagnosed
by biopsy more frequently had at presentation cognitive dysfunction,
greater cerebrospinal fluid total protein concentrations, less frequent
cerebral infarcts, and more frequent leptomeningeal gadolinium-
enhanced lesions on magnetic resonance imaging (MRI), along with
less mortality and disability at last follow-up. The patients diagnosed by
angiograms more frequently had at presentation hemiparesis or a
persistent neurologic deficit or stroke, more frequent infarcts on MRI
and an increased mortality. These differences were mainly related to the
different size of the vessels involved in the 2 groups. Although most
patients responded to therapy with glucocorticoids alone or in conjunc-
tion with cyclophosphamide and tended to improve during the follow-up
period, an overall increased mortality rate was observed. Relapses
occurred in one-quarter of the patients and were less frequent in patients
treated with prednisone and cyclophosphamide compared with those
treated with prednisone alone. The mortality rate and degree of dis-
ability at last follow-up were greater in those with increasing age,
cerebral infarctions onMRI, angiographic large vessel involvement, and
diagnosis made by angiography alone, but were lower in those with
gadolinium-enhanced lesions on MRI and in those with cerebral amy-
loid angiopathy. The annual incidence rate of PCNSV was estimated at
2.4 cases per 1,000,000 person-years. PCNSV appears to consist of
several subsets defined by the size of the vessels involved, the clinical
characteristics at presentation, MRI findings, and histopathological
patterns on biopsy. Early recognition and treatment may reduce poor
outcomes.
(Medicine 94(21):e738)
Abbreviations: ABRA = Ab-related angiitis, BACNS = benign
angiopathy of the CNS, CAA = cerebral amyloid angiopathy,
CAA-RI = cerebral amyloid angiopathy-related inflammation, CNS
= central nervous system, CSF = cerebrospinal fluid, ESR =
erythrocyte sedimentation rate, PCNSV = primary central nervous
system vasculitis, RCVS = reversible cerebral vasoconstriction
syndrome.
INTRODUCTION
P rimary central nervous system vasculitis (PCNSV) is anuncommon and poorly understood disease that affects the
brain and spinal cord. The earliest report of a case consistent
with PCNSV was by Harbitz in 1922.1 Later reports were
published under a variety of names including ‘‘noninfectious
granulomatous angiitis of the nervous system’’,2 ‘‘giant cell
arteritis of the central nervous system’’,3 ‘‘isolated angiitis of
the central nervous system’’,4 and ‘‘primary angiitis of the
central nervous system’’.5 The outcome in early reports was
usually fatal as the diagnosis was made at autopsy.1–3,6–8 Later,
biopsies and angiograms were also used to make the diagno-
sis.4,5,9–11
In 1988, Calabrese and Mallek suggested diagnostic
criteria for PCNSV. These included the development of a
neurologic deficit unexplained by other processes, plus the
presence of either an angiogram with characteristic features
of vasculitis, or a central nervous system (CNS) biopsy showing
vasculitis.5 Because of the more invasive nature of CNS biopsy,
the majority of reported cases have been diagnosed by angio-
graphy. However, the accuracy of angiography remains uncer-
tain because changes typical of vasculitis can also be seen in
nonvasculitic disorders.10–15 For example, patients with the
reversible cerebral vasoconstriction syndrome, the most com-
mon mimicker of PCNSV, may have angiographic lesions
similar to those observed in PCNSV.11,16–18 Recent published
series have improved the knowledge on this vasculitis19–21;
however, there are still uncertainties regarding its clinical
spectrum, the response to treatment, and its long-term outcome.
Several years ago we reported the results of a retrospective
analysis of 101 patients with PCNSV examined at the Mayo
Clinic over a 21-year period (1983–2003).21 In the present
study, we extended the previous cohort of PCNSV patients to
include the period from 2004 to 2011. The aim of this study was
to describe the characteristics of this enlarged cohort of patients
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with PCNSV which represents the largest study of PCNSV
reported in adults.
PATIENTS AND METHODS
Identification of the Patients
For this study, we extended our earlier PCNSV cohort of
101 consecutive patients examined at the Mayo Clinic (Roche-
ster, MN) over the 21-year period from 1983 to 200321 to 29
years, from 1983 to 2011. The same predefined diagnostic and
exclusion criteria that were used previously21 were used to
expand this retrospective cohort of PCNSV cases by including
those examined at the Mayo Clinic from January 1, 2004
through December 31, 2011. During the recent review period,
62 additional patients fulfilled the diagnostic criteria for
PCNSV. Therefore, 163 patients with PCNSV examined at
the Mayo Clinic from 1983 to 2011 were included in this
retrospective analysis. In this cohort study, we followed the
Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) recommendations for reporting descrip-
tive observational studies.22 The study was approved by the
Mayo Clinic institutional review board.
Patients were considered to have definite PCNSV if a brain
or spinal cord biopsy sample showed vasculitis (transmural
destructive inflammatory infiltrate) or if angiograms showed
changes that were highly suggestive of vasculitis (smooth-wall
segmental narrowing, dilatation or occlusion affecting multiple
cerebral arteries in the absence of proximal vessel changes
consistent with atherosclerosis).21 Angiograms were also
divided into 2 groups: large/proximal artery (intracranial
internal carotid and vertebral arteries, basilar artery, and prox-
imal anterior, middle, and posterior cerebral arteries) and small/
distal artery (intracranial artery and second division branches or
smaller). We excluded patients with vasculitis in organs other
than the CNS and those with evidence of other diseases such as
systemic lupus erythematosus and infection. None of the
patients had a history of exposure to vasoactive substances,
were in the postpartum state, had migraine headaches, thunder-
clap headaches, or manifestations typical of reversible cerebral
vasoconstriction syndrome (RCVS).17 Because the majority of
our cases were included on the basis of angiographic changes in
multiple intracranial arteries without tissue confirmation, we
were particularly careful to try to exclude cases with findings
of RCVS.
Review of Biopsy Specimens and Angiograms
Biopsy specimens were reviewed by 2 pathologists
(D.V.M. and C.G.), and angiograms were reviewed by a neu-
roradiologist. All biopsy specimens were reviewed in the same
detailed manner. Conventional digital subtraction angiogram
was the standard angiogram and was performed and interpreted
by a defined clinical protocol used by the Division of Neuror-
adiology at the Mayo Clinic, which was not specifically
designed for the study of these patients.
Clinical Data Collection
In cases with an uncertain initial diagnosis, the complete
medical record was reviewed again by 2 rheumatologists (C.S.
and G.G.H.) and 1 neurologist (R.D.B.) to reach a consensus. A
standard data collection was completed for all cases. It included
comprehensive information about clinical manifestations at
presentation and during the follow-up, other medical conditions,
laboratory investigations, radiological imaging, results of CNS
biopsy or autopsy, type of, duration of, and response to treat-
ment, number of relapses, functional status at follow-up, and
cause of death. All patients had a complete neurologic exam-
ination performed by a neurologist at the time of diagnosis and
on subsequent visits, including the last visit. Cognitive dysfunc-
tion was defined as the loss of intellectual functions such as
thinking, remembering, and reasoning of sufficient severity to
interfere with daily functioning.
Definitions
Relapse was defined as a recurrence of or worsening of
symptoms of PCNSV, or evidence of worsening of existing
lesions and/or new lesions on subsequent magnetic resonance
imaging (MRI) examinations while the patient received no
medication or received a stable dosage of medication. Patients
with relapse required an increase in therapy.
To assess the effect of treatment, we used the treating
physician’s global opinion about the response to therapy that
was obtained by a review of the detailed clinical, radiological,
and laboratory data in the medical record.
The degree of disability at presentation and at the last visit
was defined by a review of the detailed clinical data in the
medical record and was categorized using the modified Rankin
scale.23 It is a standardized and commonly used scale which
measures disability or dependence in activities of daily living in
stroke patients. The scale consists of grades 0 to 6: 0 corre-
sponds to no signs or symptoms; 1, no significant disability
(able to carry out all usual activities, despite some symptoms);
2, slight disability (able to look after own affairs without
assistance, but unable to carry out all previous activities); 3,
moderate disability (requires some help, but able to walk
unassisted); 4, moderately severe disability (unable to attend
to own bodily needs without assistance, and unable to walk
unassisted); 5, severe disability (requires constant nursing care
and attention, bedridden, incontinent); and 6, death.
Subjects were followed until the death or their last follow-
up visit (median follow-up duration: 12mo; range: 0–13.7 y).
Statistical Analysis
Numeric parameters were compared by using a 2-sided
2-sample t test or a Wilcoxon rank-sum test when the distri-
butions were skewed. Comparisons of categorical variables
were performed using the x2 or Fischer’s exact test when cell
counts were small.
Survival was estimated with the Kaplan–Meier method,
and 1-sample log-rank test was used to compare observed
survival with survival of an age- and sex-matched reference
population of whites in the United States.24
The Cox proportional hazards model was used to assess the
relation between demographic, clinical, laboratory, radiologi-
cal, pathological, and therapeutic parameters at diagnosis and
survival. We reported ‘‘crude’’ and age-controlled univariate
hazard ratios (HRs) and 95% confidence intervals (CIs). Logis-
tic regression models were used to identify characteristics at
diagnosis that increased the odds of a poor outcome. Overall
univariate and age-controlled univariate odds ratios (ORs) and
95% CIs were reported.25
The estimated incidence rate of PCNSV in Olmsted
County, Minnesota, was calculated using the estimates of
country population. The rate reported herein was weighted
by age and sex to reflect an underlying population that was
demographically comparable with the US white population.
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All P values were 2-sided; significance was defined at
P< 0.05. The statistical analysis was performed using SAS,
version 8 (SAS Institute INC., Cary, NC).
Rankin scores were dichotomized into 0 to 3 and 4 to 6
because it was medically relevant. Patients with Rankin score
between 0 and 3 maintain some degree of independence in the
activities of daily living, while patients with score >3 need
complete assistance.
RESULTS
Patients and Diagnosis
From 1983 to 2011, a total of 163 patients examined at
Mayo Clinic Rochester fulfilled the diagnostic criteria for
PCNSV (Table 1). The first column of Table 1 includes the
results for the entire cohort and the next 2 columns the results
according to the diagnosis by tissue examination or angiogram.
Several subsequent tables are arranged in the same manner.
There were 89 women and 74 men in the study. The mean
overall age at the diagnosis was 48 years, with a wide range
extending between 17 and 85 years. The median duration of
time from onset of symptoms to diagnosis was 0.1 year (median:
0.08–5.2). At the time of diagnosis, 1 patient also was found to
have chronic lymphocytic leukemia in addition to the PCNSV.
The leukemia did not appear to influence the manifestations or
course of the vasculitis.
In 105 patients, the diagnosis was established by cerebral
arteriograms, including 82 who did not have biopsies taken and
23 whose biopsies were negative. In 58 others, the diagnosis
was made by histologic examination of CNS tissue which
showed vasculitis. In 24 of the 58 patients with a tissue
diagnosis of vasculitis an angiogram was also done, but was
positive only in 8 (Table 2).
Clinical Findings
Table 1 lists the clinical manifestations at diagnosis. A
broad variety of neurologic symptoms and findings were pre-
sent. Most patients had multiple manifestations. Headache and
cognitive dysfunction were the most common symptoms at
presentation, followed by hemiparesis, persistent neurologic
deficit or stroke, and visual symptoms. Each of the above-
mentioned symptoms was present in more than one-third of the
163 patients. Prominent constitutional symptoms which might
reflect the localized intracranial inflammatory process, and
fever, were present in <10%. Eight patients had neurological
deficits with imaging related to spinal cord lesions.
Most manifestations listed in Table 1 occurred with similar
frequency in both diagnostic groups. However, some were
significantly more common in those diagnosed by biopsy or
by angiogram (Table 1). Patients with positive CNS biopsy had
higher frequencies of a cognitive dysfunction (P¼ 0.014),
whereas those diagnosed by angiogram had higher frequencies
of hemiparesis (P¼ 0.0001), a persistent neurologic deficit or
stroke (P¼ 0.0005), transient ischemic attacks (P¼ 0.039), and
visual field defect (P¼ 0.02). Other differences between the
groups were not significant.
The main initial symptom of each patient was also eval-
uated (data not shown). Persistent neurologic deficit or stroke,
headache, and altered cognition were the most common initial
symptoms. These 3 symptoms together were the initial mani-
festations in 71% of patients. In the patients diagnosed by
biopsy, altered cognition was more frequent than in those
diagnosed by angiogram (21% vs 10.5%, P¼ 0.09), while
persistent neurologic deficit or stroke was more common in
the patients diagnosed by angiography (36% vs 14%,
P¼ 0.002). The frequency of patients having headache as the
main initial manifestation was similar in both groups (29% vs
TABLE 1. Clinical Manifestations at Presentation in 163 Consecutive Patients With PCNSV
Findings
All Patients
(n¼ 163), n (%)
Biopsy Confirmed
(n¼ 58), n (%)
Angiogram Confirmed
(n¼ 105), n (%)
Headache 97 (59.5) 31 (53.4) 66 (62.9)
Cognitive dysfunction 88 (54) 39 (67.2) 49 (46.7)

Hemiparesis 66 (40.5) 10 (17.2) 56 (53.3)

Persistent neurologic deficit or stroke 66 (40.5) 13 (22.4) 53 (50.5)

Aphasia 40 (24.5) 15 (25.9) 25 (23.8)
Transient ischemic attack 42 (25.8) 9 (15.5) 33 (31.4)

Ataxia 31 (19) 6 (10.3) 25 (23.8)
Seizures 33 (20.2) 16 (27.6) 17 (16.2)
Visual symptoms (any kind) 61 (37.4) 14 (24.1) 47 (44.8)
Visual field defect 30 (18.4) 5 (8.6) 25 (23.8)

Diplopia (persistent or transient) 23 (14) 7 (12.1) 16 (15.2)
Blurred vision or decreased visual acuity 18 (11) 3 (5.2) 15 (14.3)
Monocular visual symptoms or amaurosis fugax 2 (1.2) 1 (1.7) 1 (1)
Papilledema 7 (4.3) 4 (6.9) 3 (2.9)
Intracranial hemorrhage 16 (9.8) 5 (8.6) 11 (10.5)
Amnestic syndrome 10 (6.1) 5 (8.6) 5 (4.8)
Paraparesis or quadriparesis 8 (4.9) 5 (8.6) 3 (2.9)
Parkinsonism or extrapyramidal signs 1 (0.6) 0 1 (1)
Constitutional symptomsy 15 (9.2) 6 (10.3) 9 (8.6)
Fever 16 (9.8) 8 (13.8) 8 (7.6)
Excepted where indicated otherwise, values are the number (%) of patients. PCNSV¼ primary central nervous system vasculitis.
Significant differences between biopsy-diagnosed patients and angiography-diagnosed patients.
yDefined as the presence of at least 1 of the following: fatigue, arthralgia, anorexia, and weight loss.
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29%). None of these patients, in particular those with negative
biopsy, described the headache as a thunderclap headache.
Laboratory Investigations
An erythrocyte sedimentation rate (ESR) was performed in
137 patients and was elevated above normal level (>30mm/h)
in 24 patients (17.5%), 6 (13%) in the group diagnosed by
biopsy, and 18 (19.8%) in those diagnosed by angiograms. The
median ESR value was 8mm/h (range: 0–124mm/h). C-reac-
tive protein was performed in 58 patients and it was elevated in
19 (33%) patients. Rheumatoid factor (110/113) and antinuclear
antibodies (121/131) were usually negative. Tests for antineu-
trophil cytoplasm antibodies (ANCA; 107 patients), extractable
nuclear antigen antibodies (109 patients), lupus anticoagulant
(99 patients), serum complement (95 patients), cryoglobulins
(24 patients), and HIV (97) were all normal or negative.
Cerebrospinal fluid (CSF) specimens were obtained for
analysis in 126 patients (Table 3). Spinal fluid showed 1 or more
abnormal findings in 93% of patients. In the majority of patients,
the changes included a mild elevation of the leukocyte count or
total protein concentration, or both. In those whose diagnosis was
made by biopsy compared with angiography, spinal fluid leuko-
cyte counts were higher (median 16/mL vs 4/mL, P< 0.001), as
was total protein concentrations (98mg/dL vs 56mg/dL,
P< 0.001). Spinal fluid total protein was >70mg/dL in 52%
of the samples, 77% in cases diagnosed by biopsy, and 36.5% of
those diagnosed by angiograms (P¼ 0.0001). Overall, the fre-
quent spinal fluid alterations suggested the presence of a CNS
process but there were no characteristic changes in patients with
PCNSV to help with the specific diagnosis.
Radiologic Imaging
Cerebral Angiograms
Cerebral angiograms were performed in 129 of the 163
patients (Table 2) and 113 (88%) showed changes characteristic
of vasculitis. Angiograms alone confirmed the diagnosis in 105
patients but were also positive in 8 additional patients who had
brain biopsies showing vasculitis. Angiogramswere normal in 16
other patients who had positive brain biopsies suggesting in those
that the involvedvesselswere too small tobevisualized. In all 113
patients with positive angiograms, abnormalities were present in
multiple vesselswhichwere bilateral in 108 (95.6%) (Table 4). In
the majority of instances, both large and small vessel changes
were found; however, small vessel changes were more common,
occurring in 103 (91.2%), compared with 75 (66.4%) for large
vessels. Small vessel changes were also more often bilateral
(82.3%) than largevessel alterations (54.9%).Of the75with large
vessel involvement, only 11 showed large vessel involvement
alone, while of the 103 with small vessel involvement, 39
angiograms showed only small vessel involvement.
Magnetic Resonance Imaging
MRI was performed initially in 149 of the 163 patients
(91%) and was abnormal in 143 (96%) (Table 5). Infarctions
TABLE 3. CSF Findings
All Patients
(n¼ 126), n (%)
Biopsy Confirmed
(n¼ 47), n (%)
Angiogram Confirmed
(n¼ 79), n (%)
Median leukocyte count (range), cell/mL 6 (0–615) 16 (0–535) 4 (1–615)y
Leukocyte count >5 cells/mL, number of patients/total 63/122 (51.6) 33/47 (70.2) 30/75 (40)
Median total protein concentration

(range), mg/dL 72 (15–1034) 98 (29–1034) 56 (15–242)y
Total protein concentration >45 mg/dL, number of patients/total 96/121 (79.3) 44/47 (93.6) 52/74 (70.3)
Median red blood cell count (range), cells/mL 7.5 (0–40,000) 10.5 (0–15,000) 7 (0–40,000)
Red blood cell count >0/mL, number of patients/total 96/116 (82.8) 36/44 (81.8) 60/72 (83.3)
Increased total protein concentration, leukocyte count, or red
blood cell count, number of patient/total
114/123 (92.7) 45/47 (95.7) 69/76 (90.8)
Protein >45 mg/dL, or leukocyte >5 cells/mL, number of
patients/total
100/123 (81.3) 44/47 (93.6) 56/76 (73.7)
Total protein concentration >70 mg/dL, number of patients/total 63/121 (52.1) 36/44 (76.6) 27/74 (36.5)y
Protein >70 mg/dL, or leukocyte >10 cells/mL, number of
patients/total
77/121 (63.6) 38/47 (80.9) 39/74 (52.7)
CSF¼ cerebrospinal fluid. Except where indicated otherwise, values are the number (%) of patients.
Normal range of protein is 14–45mg/dL.
y Significant differences between biopsy-diagnosed patients and angiography-diagnosed patients.
TABLE 2. Diagnostic Test Findings in 163 Consecutive
Patients With PCNSV
Finding
Patients N¼ 163,
n (%)
Angiogram positive, CNS
biopsy not done
82 (50.3)
Angiogram positive, CNS
biopsy negative
23 (14.1)
CNS biopsy positive,
angiogram positive
8 (4.9)
CNS biopsy positive,
angiogram negative
16 (9.8)
CNS biopsy positive

,
angiogram not performedy
34 (20.9)
CNS¼ central nervous system, PCNSV¼ primary central nervous
system vasculitis.
For 2 patients, pathology confirmation was at the time of autopsy.
yAngiographic evaluation was not performed within 3 months of
diagnosis by biopsy.
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were the most common type of lesion and were seen in 81 (54%)
of the 143 patients.Multiple infarctionswere found in 72 of the81
with infarctions (89%), whereas single infarctions were noted in
only 9. In those withmultiple infarctions, the lesions tended to be
bilateral (60 of the 72, or 83%). Both the cortex and subcortex (40
of the 60, or 67%)weremore frequently involved in patients with
multiple, bilateral infarcts. Intracranial hemorrhage was uncom-
mon, 12 patients (8%) had intracerebral hemorrhage at diagnosis,
while only 4 (3%) had subarachnoid hemorrhage. Gadolinium-
enhanced intracranial lesions occurred in 23% of the patients. In
29 (19.5%) patients, meningeal gadolinium-enhanced lesions
were observed. Patients diagnosed by angiography compared
with those diagnosed by biopsy had significantly more infarcts
(P¼ 0.0003), while patients diagnosed by biopsy had signifi-
cantly more frequent meningeal gadolinium-enhanced lesions
(P¼ 0.0001).
Fifty-eight patients had both conventional angiography and
a magnetic resonance angiography (MRA) performed. In 44
instances, both showed evidence of vasculitis, in 8 the angiogram
was positive and MRA normal, and in 6 both were normal.
CNS Histopathology
Brain or spinal cord tissue (1 patient had spinal cord and 1
spinal nerve root biopsies) was obtained in 81 patients and
showed vasculitis in 58 cases (72%). The 23 with no evidence of
vasculitis on biopsy showed evidence of vasculitis on angio-
graphy. A granulomatous inflammatory histologic pattern was
found in 34 patients (59%) (accompanied by vascular deposits
of b-amyloid peptide in 20 [34%]) (Figure 1A), a granuloma-
tous and necrotizing pattern in 1 (2%), an acute necrotizing
pattern in 10 (17%) (Figure 1C), and a lymphocytic pattern in 13
(22%). A bad outcome (Rankin score 4 and 5, and death) at last
follow-up was observed in 0/13 patients with lymphocytic
vasculitis, 7/35 (20%) with granulomatous vasculitis, and
3/10 (30%) with necrotizing vasculitis. We registered a trend
toward a reduction in the percentage of patients with bad
outcome at last follow-up in the lymphocytic vasculitis group
compared with granulomatous and necrotizing groups (0% vs
22.2%), but the difference did not reach statistical significance
(¼0.096). No patients died in the group with lymphocytic
vasculitis at last follow-up compared with 5/45 (11.1%) in
the other 2 groups; however, the difference was not statistically
significant (P¼ 0.577). Pathologic findings and correlations are
described in more detail elsewhere.26–29
Therapy
Of the 163 patients, 159 received treatment and 4 were
given no specific therapy. The first patient was not treated for
TABLE 4. Characteristics of 113 Positive Cerebral Angiograms
All Patients

(N¼ 113),
n (%)
Biopsy Confirmed
(N¼ 8), n (%)
Angiogram Confirmed
(N¼ 105), n (%)
Bilateral vasculitis 108 (95.6) 7 (87.5) 101 (96.2)
Large-vessel changes consistent with vasculitis
Total 75 (66.4) 5 (62.5) 70 (66.7)
Unilateral 13 (11.5) 0 13 (12.4)
Bilateral 62 (54.9) 5 (62.5) 57 (54.3)
Small vessel changes consistent with vasculitis
Total 103 (91.2) 7 (87.5) 96 (91.4)
Unilateral 10 (8.8) 0 (0) 10 (9.5)
Bilateral 93 (82.3) 7 (87.5) 86 (81.9)
Angiographic test was performed within 3 months of diagnosis. All changes involved multiple vessels. Excepted where indicated otherwise, values
are the number (%) of patients.
Of the 129 patients who underwent cerebral angiography, 113 (88%) had findings consistent with vasculitis (8 of the 24 diagnosed by biopsy also
had positive angiographic findings).
TABLE 5. Neuroimaging Findings at Diagnosis
All Patients (N¼ 149),
n (%)
Biopsy Confirmed
(N¼ 53), n (%)
Angiogram Confirmed
(N¼ 96), n (%)
Presence of infarct 81 (54.4) 18 (34) 63 (65.6)

Single infarct 9 (6) 4 (7.5) 5 (5.2)
Multiple infarcts in the same hemisphere 12 (8.1) 4 (7.5) 8 (8.3)
Multiple infarcts bilaterally 60 (40.3) 10 (18.9) 50 (52.1)
Gadolinium-enhanced lesions (intracerebral or meningeal) 60 (40.3) 39 (73.6) 21 (21.9)
Intracerebral gadolinium-enhanced lesions 34 (22.8) 18 (34) 16 (16.7)
Meningeal gadolinium-enhanced lesions 29 (19.5) 23 (43.4) 6 (6.3)

Intracerebral hemorrhage 12 (8.1) 5 (9.4) 7 (7.3)
Subarachnoid hemorrhage 4 (2.7) 0 4 (4.2)
Excepted where indicated otherwise, values are the number (%) of patients.
Significant differences between biopsy-diagnosed patients and angiography-diagnosed patients.
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concurrent Candida glabrata sepsis and enterocutaneous fistula
secondary to a small bowel resection for repair of adhesions due
to radiation therapy for endometrial cancer. PCNSV diagnosis
was confirmed by 2 cerebral angiograms. The neurological
condition apparently was stable, but the patient died 9 months
later from unknown cause. The second patient had a mild
clinical presentation (headache, numbness in upper and lower
limbs, and fatigue) that spontaneously improved before the
diagnosis. At last follow-up, 5 months later, the patient was
in remission without treatment. The third patient was not treated
because when the cerebral biopsy was performed (evidence of
granulomatous vasculitis) the patient also had a ventriculoper-
itoneal shunt for raised intracranial pressure with marked
improvement of neurological symptoms (papilledema and
headache). Follow-up data on this patient were not available.
The fourth patient was not treated because she had, initially, a
diagnosis of biopsy proven cerebral amyloid angiopathy
(CAA), the diagnosis of Ab-related angiitis (ABRA) was made
after the biopsy revision at Mayo Clinic 5 years later.
Glucocorticoid therapy was prescribed for 157 patients. In
66 of the 157 patients, intravenous pulse glucocorticoid doses
were given before or at the time oral prednisone was started.
Methylprednisolone, generally 3 to 5 pulses of 1 g/pulse was
given most commonly. The median initial oral prednisone dose
was 60mg/d. The median length of oral prednisone therapy was
9 months. Three-quarters of patients were treated for 17 months
or less. In 75 patients, glucocorticoids were the only therapeutic
agent used initially. In 82 patients, another drug was given with
prednisone. In 72 patients, the second drug was cyclopho-
sphamide, given orally daily in 49 patients and by intermittent
intravenous pulses in 23 patients. The median starting dose of
oral cyclophosphamide was 150mg/d and median length of
treatment was 7 months. The median dose of intravenous pulse
cyclophosphamide was 1000mg/mo.
The patients initially treated with cyclophosphamide and
prednisone compared with those treated with prednisone alone
had a higher frequency at diagnosis of persistent neurologic
deficit or stroke (52% vs 27%, P¼ 0.005) and infarcts at MRI
(61% vs 43%, P¼ 0.05), while the frequency of seizures was
lower (6% vs 33%, P¼ 0.0001). Furthermore, high disability
scores (Rankin score 4 and 5) at presentation were more
frequent in patients treated with cyclophosphamide and pre-
dnisone compared with those treated with prednisone alone
(39% vs 20%, P¼ 0.01).
Six of the 82 patients were started on prednisone plus
azathioprine at a median starting dose of 100mg/d. Three
patients received mycophenolate mofetil with prednisone and
one patient rituximab. Two of the 163 patients received oral
cyclophosphamide without glucocorticoids.
Of the 75 patients given prednisone alone initially, the
records contained adequate information to judge the response at
follow-up in 73, which was recorded as favorable in 62 (85%).
To assess the response to cyclophosphamide, patients
started on oral and intravenous pulses were grouped together
because of the small number of patients. In 69 of the 72 patients
treated with cyclophosphamide and prednisone, the records
provided adequate information to determine response. A favor-
able response to therapy was recorded in 55 (80%).
The response to treatment in those given prednisone alone
was not different between the group with biopsy-diagnosed
disease and the group with angiographically diagnosed disease
or did not vary according to histopathologic pattern. The results
were the same in patients given prednisone plus cyclopho-
sphamide. It should be recognized that the numbers in the
various groups analyzed were quite small. Further description
of treatment is provided elsewhere.30,31
The experience in this cohort with azathioprine plus pre-
dnisone and mycophenolate and prednisone was limited; how-
ever, the available data suggested that both regimens were also
effective.30,31
Forty-four of the 159 patients had relapses leading to an
increase or change in therapy. Twenty-eight of the 44 had one
FIGURE 1. Pathological findings in primary central nervous system vasculitis and cerebral amyloid angiopathy-related inflammation
(CAA-RI). (A) Granulomatous pattern with amyloid angiopathy (ABRA). Transmural inflammation, often granulomatous, associated with
vascular wall disruption (upper; hematoxylin and eosin [H&E] stain) and amyloid-b deposition (lower; immunoperoxidase stain for bA4
amyloid) is typical of ABRA. (B) CAA-RI pattern. Mild perivascular inflammation often with giant cells surrounding leptomeningeal and
cortical small vessels (upper; H&E stain) with vascular amyloid deposition (lower; immunoperoxidase stain for bA4 amyloid) is
characteristic of CAA-RI. (C), Necrotizing pattern. A segment of intraparenchymal muscular artery shows extensive mural necrosis with
karyorrhetic debris and acute neutrophilic inflammation (H&E).
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relapse, 10 had 2, and 6 had 3 or more relapses. No specific
clinical symptoms, laboratory tests, or histopathologic findings
were identified with those who had relapses. However, relapses
were more common in patients treated initially with prednisone
alone compared with those treated with cyclophosphamide and
prednisone (39% vs 18%, P¼ 0.006). Patients with relapses
were treated longer that those without relapses. The median
length of treatment in those with relapses was 18 months, while
in those without relapses the median length of therapy was
9 months (P¼ 0.0001).
No significant differences in the frequency of relapsing
disease were observed between patients whose diagnosis was by
biopsy or by angiography [18/54 (33%) versus 26/99 (26%),
P¼ 0.357]. Relapses were observed in 22/71 (31%) patients
with large-vessel involvement on angiography and in 12/51
(24%) patients with only small-vessel changes on angiography
or angiography-negative and biopsy-positive cases (P¼ 0.417).
Outcome
The median duration of follow-up of the 163 patients was
12 months with a range from 0 to 13.7 years. At the end of the
follow-up period, 138 patients were alive and 25 (15%) had
died. The cause of death in the 25 patients was cerebral
infarction in 10, stroke of undefined type in 1, myocardial
infarction in 1, respiratory complication in 3, malignancy in 1,
and unknown cause in 9.
Figure 2 shows an estimated age- and gender-matched
survival curve of the PCNSV patients versus that expected of
the age-matched US white population. Survival among the
patient cohort is significantly reduced (P< 0.001).
Univariate logistic modeling was used to assess the associ-
ation of clinical findings at diagnosis with the Rankin score
outcomes at last follow-up (Table 6). High disability scores
(Rankin score 4–6) at last follow-up were associated with
increasing age (OR, 1.44) and cerebral infarction observed
on MRI at presentation (OR, 3.74). Patients with gadoli-
nium-enhanced meninges or lesions on MRI (OR, 0.35) and
those with amyloid angiopathy (OR, 0.24) had lower disability
at follow-up. High disability scores at last follow-up were more
frequent in angiography-diagnosed patients than biopsy-diag-
nosed (27/105, 26% vs 10/58, 17%), but the difference was not
significant. Those treated with prednisone versus prednisone
plus cyclophosphamide had similar outcomes.
Univariate Cox proportional hazards modeling was used to
assess the association of survival with clinical findings at the
time of diagnosis. The clinical findings analyzed were the same
as those evaluated for disability outcome (mentioned earlier).
Four findings were associated with an increased mortality rate.
These were increasing age (calculated per 10-y increments; HR,
1.39; 95% CI: 1.05–1.85; P¼ 0.02), diagnosis by angiography
only compared with biopsy (HR, 3.28; 95% CI: 1.09–9.82;
P¼ 0.03), cerebral infarction observed on MRI compared with
those without an infarction (HR, 4.44; 95% CI: 1.61–12.2;
P¼ 0.004), and the presence of large vessel involvement on
angiograms (HR, 4.98; 95% CI: 1.47–16.9; P¼ 0.01). Patients
with gadolinium-enhanced lesions or meninges onMRI had less
risk of death during follow-up than patients who had no such
lesions on MRI at presentation (HR, 0.20; 95% CI: 0.06–0.67;
P¼ 0.009), as did patients with ABRA (HR, 0.17; 95% CI:
0.02–1.33); however, only a statistical trend was observed
(P¼ 0.09).
There was no difference in survival between those treated
with prednisone alone and those given prednisone plus cyclo-
phosphamide, and different presenting manifestations.
Annual Incidence Rate of PCNSV
Eight of the 163 patients were residents of Olmsted County
at the time PCNSV developed. The calculated annual incidence
rate for these cases was 2.4 cases per 1,000,000 person-years
(95% CI: 0.7–4.1) age- and sex-adjusted to 2000 US white
population.
Comparison Between 1983–2003 and
2004–2011 Cohorts
We compared the 101 patients identified in the period 1983
to 2003 with the 62 identified in the period 2004 to 2011 to
evaluate possible differences in demographic, clinical presen-
tation, diagnostic modalities, types of treatment, and outcomes.
No differences in males/females ratio were observed
(43/58 vs 29/33, P¼ 0.600). The median age at diagnosis
was significantly higher in the new cohort of patients (51.5 y,
range: 20–85 y, vs 47 y, range: 17–84 y, P¼ 0.016). Time from
onset to diagnosis was similar in the 2 groups (0.1 y, range:
0.0–5.2 y, vs 0.1 y, range: 0.0–5.2 y, P¼ 0.708). No differences
in clinical manifestations at diagnosis were observed in the 2
cohorts of patients: headache (53.2% vs 63.4%, P¼ 0.200) and
cognitive dysfunction (61.3% vs 49.5%, P¼ 0.143) were the
most common symptoms. The new cohort had a higher fre-
quency of patients with meningeal gadolinium-enhanced
lesions (30.5% vs 12,2%, P¼ 0.006), a reduced frequency of
patients with large vessel changes at angiography (52.6% vs
72.4%, P¼ 0.036), and a higher percent of patients with MRA
examinations (61.3% vs 31.7%, P¼ 0.0001), performed within
3 months of diagnosis. Also, the new cohort had a higher level
of disability (Rankin score 4 and 5) at presentation (43.5% vs
21.8%, P¼ 0.013) and at last follow-up (14.5% vs 3%,
P¼ 0.022), but mortality was not different at last follow-up
(12.9% vs 16.8%), nor was frequency of bad outcome (Rankin
score 4–6) at last follow-up (27.4% vs 19.8%, P¼ 0.259). No
differences between the 2 groups were observed for laboratory
investigations, including CSF analysis, histopathological pat-
terns, and treatment. Treatment and disease course in the 2
groups are described in more detail elsewhere.30
FIGURE 2. Estimated age- and gender-adjusted survival of
primary central nervous system vasculitis (PCNSV) patients versus
that expected of the US white population. Survival among PCNSV
patients is significantly reduced (P<0.001).
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Selected Index Cases Illustrative of the Different
Presentation of PCNSV
In our cohort of patients with PCNSV, we identified
specific subsets that appear to differ in terms of prognosis
and optimum treatment. Several cases which illustrate features
in some of the variants are described in the following sections.
Case 1. Rapidly Progressive PCNSV
A 47-year-old previously healthy man was admitted to the
St Marys Hospital in February 2009 with bilateral strokes. His
clinical status improved and he was dismissed. Ten days later he
was readmitted with lethargy and a progressing right hemipar-
esis. Normal laboratory tests included ESR (3mm/h; normal
values: 0–22mm/h), blood coagulation studies, antinuclear
antibody panel, cryoglobulins, antiphospholipid antibodies
(including lupus anticoagulant), and ANCA. Serology tests
(for hepatitis B, hepatitis C, and human immunodeficiency
virus [HIV]), and a fungal serology survey were negative.
CSF protein concentration was 69mg/dL (normal 14–45mg/
dL), erythrocyte count was 528/mL, and white blood cell count
was 22/mL (1% neutrophils, 85% lymphocytes, and 14%mono-
cytes). MRI showed the presence of multiple infarcts of various
ages, including the lateral basal ganglia bilaterally and within
the right parietal and occipital lobes bilaterally. MRA showed
stenoses in multiple cerebral arteries. A conventional angio-
gram confirmed the presence of multiple bilateral narrowings in
the left anterior cerebral artery, right and left middle cerebral
arteries (MCA), and left posterior cerebral artery and their
territories. Findings on chest radiographs, transesophageal
echocardiogram, and duplex carotid ultrasonography were
unremarkable. The patient had no history of exposure to vaso-
active substances, thunderclap headaches, or other manifes-
tations typical of RCVS. A diagnosis of PCNSV was made and
the patient was treated with intravenous methylprednisolone
(1 g/d for 5 d) followed by prednisone 60mg/d, and IV cyclo-
phosphamide (1 pulse of 1.5 g). However, despite the treatment,
his neurological status continued to deteriorate, and he became
unresponsive and was intubated. A second MRI, performed
7 days after the first, showed interval progression of themultiple
areas of restricted water diffusion with several new areas of
restriction involving a large wedge-shaped area of the right
parieto-occipital region and several smaller focal areas invol-
ving the right basal ganglia, left paramedian cerebral hemi-
sphere, posterior left centrum semiovale, posterior right frontal
lobe, right parietal region, and right temporal lobe. One week
later he died.
Comment: This case exemplifies the worst end of the
clinical spectrum of PCNSV. Rapidly progressive PCNSV often
has, as in our patient, a fatal outcome.32,33 These patients are
characterized by bilateral, multiple, large cerebral vessel lesions
on angiograms and multiple bilateral cerebral infarctions fre-
quently involving both the cortex and subcortex. The predo-
minant vascular histopathological pattern is granulomatous and/
or necrotizing.32 PCNSV diagnosed in our patient was sup-
ported by angiographic changes highly suggestive of vasculitis,
the clinical course and spinal fluid analysis. A careful clinical
history that excluded the exposure to vasoactive substances and
the absence of thunderclap headache made the diagnosis of
RCVS improbable but a biopsy was not performed.18 The
diagnosis of rapidly progressive PCNSV requires a high degree
of clinical awareness. In this condition, an aggressive therapy
with intravenous pulse methylprednisolone and cyclophospha-
mide is recommended and should be started as soon as possible.
Case 2. Intracranial Hemorrhage and Spinal Cord
Involvement
In March, 2001 a 37-year-old woman with well-controlled
Crohn disease had a brief episode of nausea, vertigo, unsteadi-
ness, transient headache, and generalized fatigue. Three months
later she suddenly developed severe vertigo with nausea, vomit-
ing, dysarthria, and severe headache. By next morning, she had
difficulty getting up because of these symptoms. Brain com-
puted tomography (CT) scan demonstrated acute hemorrhage
within the medial left cerebellar hemisphere and right temporal
operculum. She was hospitalized. Brain MRI without gadoli-
nium confirmed the above-mentioned findings and also old
TABLE 6. Characteristics Associated With High Disability Scores (Rankin score 4–6) at Last Follow-Up
Characteristics OR 95% CI P
Age (per 10-y difference) 1.44 1.11–1.86 0.005
Male vs. female 1.20 0.56–2.55 0.65
Main symptom at presentation
Headache or constitutional symptom 1.00
Focal manifestation vs. headache or constitutional symptom 2.57 0.90–7.35 0.079
Cognitive disorder vs. headache or constitutional symptom 3.31 0.86–12.8 0.082
Diagnosis by angiography only compared with biopsy 2.17 0.92–5.16 0.079
MRI findings
Infarct vs no infarct 3.74 1.55–9.06 0.003
Gadolinium-enhanced lesions or meninges vs. normal or minimal changes 0.35 0.15–0.86 0.02
Large-vessel involvement vs. small vessel involvement

2.12 0.86–5.18 0.10
Increased CSF protein level (>70mg/dL) 1.28 0.52–3.19 0.59
Cerebral amyloid angiopathy, presence vs. absence 0.24 0.06–0.94 0.040
Prednisone alone vs. cyclophosphamide and prednisone 0.59 0.27–1.29 0.18
Rapid (<1 mo) vs. slow onset (>1 mo) 0.95 0.43–2.09 0.90
Univariate logistic model was used for age-adjusted analysis. CI¼ confidence interval, CSF¼ cerebrospinal fluid, MRI¼magnetic resonance
imaging, OR¼ odds ratio.
For this measurement, n¼ 129.
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hemorrhages in the inferior right cerebellar hemisphere and left
parietal area. Magnetic resonance venography (MRV) and
MRA, and cerebral conventional angiography were negative.
Coagulation studies and a workup for systemic vasculitis were
negative. CSF analysis showed 320/mL erythrocytes, 50/mL
white blood cells (90% lymphocytes and 10% monocytes), and
protein concentration of 108mg/dL. A repeat brain CT per-
formed 4 days later demonstrated an increase in the hematoma
involving the right parietal operculum. A brain biopsy was
performed in the right temporal lobe with evidence of white
matter focal macrophage accumulation most suggestive of
microscopic subacute infarct, but no evidence of vasculitis or
vascular b-A4 amyloid deposition. Despite the negative biopsy,
PCNSV was suspected. The patient was treated with high-dose
intravenous methylprednisolone (1 g/d) for 3 days, and then put
on oral prednisone 60mg/d. The neurological findings
improved significantly. The prednisone was gradually tapered.
A repeat MRI 3 months later showed a reduction in the size of
right temporal hematoma, and no new hemorrhages. The pre-
dnisone treatment was stopped. After the discontinuation of the
treatment she complained of daily headaches of short duration
(several seconds to minutes) in right temporal or bifrontal
regions. Four months later, pain and numbness in both legs
and difficulty ambulating developed. She progressively lost
sensation in her legs below the knees and had numbness in
her posterior legs and buttocks. Other symptoms included
difficulty with speech, and urination and stool incontinence.
She was again hospitalized. Neurological examination showed
an ataxic gait and sensory loss in the soles extending up in the
posterior portion of the legs bilaterally and extending to the
buttocks and perineal area bilaterally. Muscle strength was
normal in the arms and mildly reduced in the legs. Mental
status examination showed mild cognitive dysfunction. Brain
MRI with and without contrast including diffusion-weighted
images showed subtle abnormal intraparenchymal perivascular
enhancement most prominent adjacent to the lateral ventricles
and in the basal ganglia and subtle pial enhancement most
prominent in the cerebellum and brainstem. No evidence of
recent hemorrhage or infarction was present. MRA of the head
was normal. The MRI of the spine without and with gadolinium
demonstrated abnormal T2 signal, mass effect and enhancement
within the conus medullaris. There was also enhancement of the
roots of the cauda equine diffusely. Tests with normal or
negative findings included ESR, serum liver enzymes, complete
blood count, creatinine, urinalysis, serum antinuclear anti-
bodies, antibodies against double-stranded DNA, ANCA,
cryoglobulins, antiphospholipid antibodies including lupus
anticoagulant, blood coagulation studies, angiotensin-convert-
ing enzyme, bacterial and fungal blood cultures, tuberculin skin
test, serology tests (Lyme disease, HIV, hepatitis virus B and C,
and syphilis) and fungal serology survey (Aspergillus, Blasto-
myces, Coccidioides,Histoplasma,CryptococcusAg, and Spor-
othrix). CSF protein was elevated (296mg/dL), erythrocyte
count was 48/mL, and white blood cell count was 59/mL
(62% lymphocytes, 25% neutrophils, and 13% monocytes).
Cytology was negative. CSF cytologic immunostaining did
not show malignant cells or features consistent with leukemia
or lymphoma. Additional CSF tests with negative results
included the venereal disease research laboratory test (VDRL),
Cryptococcus antigen test, and cultures for fungi and bacteria,
and Gram stain. A nerve root biopsy (dorsal root and first sacral)
showed necrotizing vasculitis involving small vessels associ-
ated with segmental root necrosis, and no evidence of lym-
phoma. Masson trichrome demonstrated the presence of
fibrinoid necrosis in vascular walls. Immunohistochemical
stains showed a population composed predominantly of
CD3þ reactive T lymphocytes and to a much lesser extent of
CD20þ B lymphocytes. Special stains for microorganisms
(Grocott’s methenamine silver and Gram stain) were negative.
Cultures of spinal cord cauda equina for fungi, mycobacteria,
bacteria, and anaerobes were negative, as negative were smear
for fungi, acid fast smear, and Gram stain. A diagnosis of
PCNSVwith involvement of the cauda equine wasmade and the
patient was treated with intravenous methylprednisolone (1 g/d)
for 3 days, followed by oral prednisone (60mg/d), and monthly
pulse intravenous injections of cyclophosphamide (1 g/mo).
One month later, she had an increase in lower extremity
strength, was able to walk independently with a cane, her
incontinence improved, and was beginning to regain the control
of urination, and had less pain. Monthly cyclophosphamide was
continued for 6 months. Prednisone was gradually tapered and
suspended after 8 months. Eighteen months later she had no
recurrence of symptoms attributable to vasculitis, she conducted
almost normal activities, and a repeat brain MRI showed no
new lesions.
Comment. This case exemplifies 2 possible presentations
of PCNSV. Intracranial hemorrhage is a presenting feature in
approximately 12% of patients.28 Intracerebral hemorrhage is
more common than subarachnoid hemorrhage which is a rare
manifestation of PCNSV. Evidence of cerebral infarctions on
MRI is uncommon in these patients. Necrotizing vasculitis, as
shown in this patient, is the predominant histopathological pattern
of biopsy specimens in patients with intracranial hemorrhage.
Spinal cord involvement is observed in about 5% of patients with
PCNSV, but rarely is the onlymanifestation.34Most patientswith
spinal presentation have previous (as this patient), concurrent, or
subsequent brain involvement during the disease course. The
thoracic cord is predominantly affected. Careful medical evalu-
ation should be undertaken to exclude other disorders associated
with acute or subacute transverse myelitis. Patients with intra-
cranial hemorrhage or spinal cord involvement, as shown in our
patient who associated both conditions, generally respond well to
immunosuppressive treatment.
Case 3. Prominent Leptomeningeal Enhancement
A 45-year-old previously healthy truck driver was
admitted with a 2-month history of progressive loss of memory,
confusion, and headache. He also had 2 episodes lasting
10 hours characterized by sudden weakness and anesthesia of
the entire left arm and leg. The 2 episodes were interpreted as
partial seizures. The physical examination was negative, the
neurological examination confirmed the cognitive dysfunction
with poor attention, confusion, and difficulties in short-term
memory. Blood tests with normal or negative findings included
complete hematology counts, ESR, liver enzymes, blood chem-
istries, urinalysis, antinuclear antibody panel, cryoglobulins,
anticardiolipin antibodies, blood coagulation studies (including
lupus anticoagulant), angiotensin-converting enzyme, cultures,
and numerous serology tests for viruses and fungi. CSF protein
concentration was 125mg/dL, and white blood cell count was
14 mL (76% lymphocytes, 19% neutrophils, and 5% mono-
cytes). CSF cytology for malignant cells was negative as were
studies and cultures for infectious diseases. Initial contrast
enhanced MRI of the brain showed diffuse leptomeningeal
enhancement involving both cerebral and cerebellar hemi-
spheres (Figure 3A). Head MRA and conventional cerebral
angiography were normal. An MRI-guided stereotactic brain
biopsy revealed granulomatous vasculitis of the leptomeningeal
Medicine  Volume 94, Number 21, May 2015 Analysis of Patients With PCNSV
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com | 9
vessels. No abnormalities were observed in the dura. A
b-amyloid stain was negative. PCNSV was diagnosed and
the patient was started on oral prednisone (60mg/d). Two weeks
later he was much less confused, the headache was gone, the
seizures subsided, and he was able to perform many of his
previous activities. One month later repeat MRI showed a
marked reduction of the leptomeningeal enhancement. The
prednisone dosage was progressively reduced and stopped
5 months later. Follow-up MRI showed the complete resolution
of the leptomeningeal enhancement (Figure 3B). Physical and
neurological examinations were normal. Nine months later, at
last follow-up, he was in complete remission without
neurological symptoms, the neurological examination was
negative and he restarted his work of truck driver.
Comment. Prominent gadolinium leptomeningeal enhan-
cement on MRI points to a distinct subtype of PCNSV with
small leptomeningeal artery vasculitis.35,36 As in this case, the
course tends to be more benign, characterized by rapid clinical
onset, frequent presence of a cognitive dysfunction, negative
angiography or MRA, and good clinical response to glucocor-
ticoid therapy with an overall favorable course. Some may have
b-amyloid peptide deposition in vessel walls.29,35–37 Definite
elevated concentration of protein in spinal fluid is another
characteristic of this subgroup of patients.
Case 4. Granulomatous Vasculitis With Cerebral
Amyloid Angiopathy (ABRA)
A 64-year-old previously health man was admitted with a
1.5-month history of severe headache, confusion, personality
change, and progressive cognitive decline. On physical exami-
nation, he was ataxic. Laboratory test findings were unremark-
able. The ESR was 2mm/h. Tests with normal or negative
results included serum antinuclear antibodies, ANCA,
antibodies against double-stranded DNA, cryoglobulins, anti-
cardiolipin antibodies, blood coagulation studies, tuberculin
skin test, serology tests (for hepatitis B, hepatitis C, and
HIV), and a fungal serology survey (Coccidioides,Histoplasma,
and Blastomyces). CSF protein concentration was 97mg/dL,
erythrocyte cell count was 50/mL, and white blood cell count
was 23/mL (90% lymphocytes and 10% monocytes). CSF
cytologic immunostaining showed no malignant cells or
features of leukemia or lymphoma. Additional CSF tests with
negative results included the VDRL, Cryptococcus antigen test,
fungal and bacterial cultures, and polymerase chain reaction
assays for herpes simplex and zoster viruses, Epstein–Barr
virus, cytomegalovirus, Toxoplasma gondii, and Borrelia burg-
dorferi. Chest radiographs, transesophageal echocardiogram,
and duplex carotid ultrasonogram were unremarkable. Initial
contrast-enhanced MRI of the brain showed diffuse bilateral
leptomeningeal enhancement involving the cerebrum and the
cerebellum, multiple infarcts, patchy T2-weighted white matter
signal abnormality. Cerebral angiography was normal. An open
brain biopsy showed granulomatous leptomeningeal and intra-
parenchymal vasculitis. Infarcts and vascular b-A4 amyloid
deposition consistent with CAA were also present (Figure 1A).
Stains of biopsy specimens were negative for fungal and
mycobacterial organisms. PCNSV, or more specifically ABRA,
was diagnosed and the patient was treated with oral prednisone
(initial dosage, 40mg/d) and monthly pulse intravenous injec-
tions of cyclophosphamide (1.7 g/mo) for 14 months. His
neurologic state progressively improved in the first 3 months.
He was much less confused, his headache resolved and he was
able to perform many of his previous activities. At this time
follow-up cranial MRI showed complete resolution of lepto-
meningeal enhancement and no new infarcts. At his final
follow-up visit 12 months later, he was no longer taking
prednisone or immunosuppressants and he had no recurrence
of symptoms attributable to vasculitis. He had only a minimal
disability and conducted normal activities.
Comment. About one-quarter of patients with biopsy-
positive PCNSV have evidence of cerebral amyloid vascular
deposition.29,37 This condition is defined as ABRA.38 As the
history showed, these patients usually have cognitive dysfunc-
tion and/or seizures/spells at presentation, higher concentrations
of CSF protein, and enhancing leptomeningeal lesions on MRI.
They usually are angiography-negative because the vasculitis is
FIGURE 3. Magnetic resonance image (MRI) showing prominent
leptomeningeal contrast enhancement. (A) MRI at symptom
onset: diffuse, asymmetric, nodular, and linear leptomeningeal
enhancement. (B) MRI after treatment: resolution of abnormal
contrast enhancement and abnormal T2 signal within the sulci.
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limited to small cortical and leptomeningeal vessels beyond the
resolution of conventional angiography. Cerebral biopsy is
required for the diagnosis. Brain biopsy samples show a gran-
ulomatous histopathological pattern plus vascular deposits of
amyloid-b. As this case demonstrates, they usually respond
favorably to treatment and have a good outcome. Early recog-
nition and treatment of ABRAwill help avoid serious outcomes.
Case 5. Amyloid Angiopathy With Perivascular
Inflammation
A 69-year-old previously healthy woman was referred to
Mayo in January 2011 with a 3-week history of three 5-minute
episodes. The first occurred upon awaking from a nap. Her right
index finger was weak and numb. There was also numbness in
the right lip and tongue, drooping of the right side of her face
with some slurring of speech. The next day she also noticed an
episode of weakness in her right leg and limping. Three weeks
later, she had the last episode characterized by sudden weakness
of her right hand. On neurological examination, the patient was
awake and alert, but had somewhat unusual affect; she had also
an impaired short test of mental status (32/38). Neuropsycho-
logical assessment showed signs of anomia, difficulty with
verbal response inhibition, and poor planning. Electroenceph-
alogram showed amoderated degree of diffuse nonspecific slow
wave abnormalities maximal temporally, but no epileptogenic
activity. Laboratory test findings were unremarkable. The ESR
was 7mm/h. Tests with normal or negative findings included
serum antinuclear antibodies, ANCA, antibodies against
double-stranded DNA, cryoglobulins, antiphospholipid anti-
bodies, blood coagulation studies, angiotensin-converting
enzyme, tuberculin skin test, and syphilis serology tests (IgG
and IgM syphilis Ab). CSF total protein concentration was
56mg/dL, the erythrocyte cell count was 13/mL, and the white
blood cell count 1/mL (59% lymphocytes, 40% monocytes, and
1% neutrophils). Cytologic findings were negative. Additional
CSF tests with negative results included antineuronal nuclear
antibody (ANNA)-1, ANNA-2, ANNA-3, antiglial nuclear
antibody-1, Purkinje cell cytoplasmic antibody (PCA)-1,
PCA-2, PCA-Tr, amphiphysin Ab, and collapsin response
mediator protein 5 Ab. A chest radiograph was unremarkable.
Contrast-enhanced MRI of the brain showed left greater than
right cerebral hemispheric leptomeningeal enhancement, the
findings were more evident in the left parieto-occipital area.
MRV and cerebral digital subtraction angiography were nega-
tive. Left parietal stereotactic cerebral biopsy directed on the
enhancing leptomeningeal lesion showed perivascular lympho-
cytic inflammation without giant cells surrounding intact lep-
tomeningeal vessels (Figure 1B). A b-amyloid stain was
strongly and diffusely positive in cortical and leptomeningeal
vessels. A diagnosis of CAA-related inflammation (CAA-RI)
was made and the patient was treated with high-dose intrave-
nous methylprednisolone (1 g/d) for 5 days, followed by oral
prednisone (60mg/d). Three months later at last follow-up she
was markedly improved, she stopped having spells, and brain
MRI showed the complete disappearance of the leptomeningeal
enhancement. She was on therapy with prednisone at a daily
dose of 40mg.
Comment. This patient was included here to demonstrate
the close clinical relationship between CAA-RI and ABRA.
CAA-RI cases are part of our report on amyloid angiopathy,29
but were not included in the current cohort of 163 patients with
PCNSV because the biopsy histopathologic appearance did not
meet the criteria for definite vasculitis. The patient presented
with findings similar to those seen in ABRA and had a favorable
response to the prednisone treatment, but biopsies are separable.
Two pathologic inflammatory reactions to the deposition of
amyloid-b in the cerebral vessels have been described: first with
a vasculitic transmural, often granulomatous, inflammation
(ABRA), and the second with a perivascular non-destructive
inflammatory infiltration, so called CAA-RI.29,39,40 ABRA and
CAA-RI more closely resemble PCNSV than CAA without
vascular inflammation and likely are part of the same pathologic
spectrum.29
DISCUSSION
Biopsy of CNS tissue showing vasculitis is the definitive
diagnostic test for PCNSV. However, many physicians have
preferred angiography in favor of biopsy because of the invasive
nature of the former41–46 even though angiograms have not
been considered specific and their sensitivity is unknown. It has
been noted on more than 1 occasion that angiographic altera-
tions similar or identical to those present in vasculitis may be
seen in association with a variety of other diseases.12,14,47,48 Of
the several reports in the literature that include 10 or more adult
cases of PCNSV, most of the diagnoses were established by
angiography.41,49–52 In 3 recent series which included 12
patients, 101 patients, and 52 patients only 1 case, 31 cases,
and 19 cases, respectively, were diagnosed using cerebral
biopsy.19,21,51 Thus, our understanding of PCNSV is based to
a considerable extent on a small number of series of cases
diagnosed predominantly by angiograms. Our present study
represents the largest reported series of cases in adults, and
largest number diagnosed by cerebral biopsy which permitted
us to compare the clinical findings in those diagnosed by biopsy
with those diagnosed by angiography. Furthermore, updating
our previous cohort with a sizeable number of new cases
strengthens the overall findings regarding the characteristics
and outcomes of PCNSV. An annual incidence rate of PCNSV
for Olmsted County could also be estimated.
To compare our cases with those previously reported, we
used similar diagnostic criteria employed by others requiring
either a biopsy with findings of vascular inflammation or an
angiogram with characteristic alterations associated with vas-
culitis along with a compatible clinical examination.5,11,13,16,21
However, to ensure including definite cases, we carefully
reviewed all biopsy specimens and accepted only conventional
angiograms clearly showing a multifocal vascular process. As a
result, 95% of cases diagnosed by angiograms showed multiple
bilateral vessel alterations suggesting vasculitis. MR angiogra-
phy was not used for diagnosis as it did not appear as sensitive as
conventional angiography. However, in the evaluation of
patients, MR angiography may be helpful when suspecting a
diagnosis of PCNSV. Using the comprehensive information
contained in the Mayo Clinical medical records and the follow-
up data available, we were able to exclude patients with
vasculitis in organs other than the CNS and those with evidence
of other diseases which can mimic PCNSV, in particular RCVS.
Clinical findings in this series, which were similar to our
previous observations and to reports by others,5,10,11,13,21
included the lack of a significant gender predisposition (56%
women in our study), the median age of onset in early middle
age (48 y), and a broad spectrum of clinical manifestations with
headache, altered cognition, aphasia, focal neurologic deficits,
and hemiparesis being most common. Also similar to earlier
works, inflammatory markers were mostly normal, reflecting
the localized intracranial nature of the inflammatory process.
Although a minority of patients had elevated ESRs (17.5%), the
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clinical findings and outcomes in these patients were not
different from those with normal ESRs (data not shown). Spinal
fluid analysis was abnormal in most (93%) of the patients.
Changes consisted of a mildly increased leukocyte and eryth-
rocyte counts and total protein concentration. Although CSF
findings were generally mild and nonspecific, they were helpful
in the patients without histological verification but with a high
probability angiogram in differentiating PCNSV from RCVS,
where CSF findings are usually normal.17,18 CSF analysis also
included in most patients appropriate stains, cultures, serolo-
gical and molecular tests, and flow cytometry studies and they
were useful to exclude infection or malignancy. MRI examin-
ations were abnormal in nearly all cases tested (143 of 149
patients). But more suggestive findings such as infarctions
occurred in a lower proportion (54%). Multiple infarctions
were seen in most of these (89%). Gadolinium-enhanced lesions
(intracerebral or meningeal) represented the second most fre-
quent MRI finding observed. Sixteen patients (10.8%) had
evidence of intracranial hemorrhage at presentation, mainly
intracerebral hemorrhage as shown in Case 2, and also
described in a previous manuscript.28 The normal results of
tests for serum antinuclear antibodies, anti-ENA, ANCA, lupus
anticoagulant, HIV infection, and other related determinations
help mainly to exclude other possible causes of the symptoms.
In this enlarged cohort, some clinical differences between
the patients diagnosed by angiography and those diagnosed by
biopsy that we found earlier now became significant (Table 1).
The patients diagnosed by biopsy more frequently had a cog-
nitive dysfunction at presentation, elevated CSF total protein
concentrations, leptomeningeal gadolinium-enhanced lesions
on MRI, and better outcomes with less mortality, but less
frequent infarctions. The patients diagnosed by angiograms
more frequently had hemiparesis or a persistent neurologic
deficit or stroke at presentation, infarctions on MRI at diagnosis
and an increased mortality. These differences were strictly
related to the different size of cerebral vessels involved by
the inflammatory process in the 2 groups. Sixteen patients had
normal angiograms and positive biopsy findings, suggesting
that vessels involved were small and beyond the resolution of
conventional angiography, while 23 others had positive angio-
graphic findings and negative biopsy suggesting that the
affected vessels were of larger size while the small cortical
and leptomeningeal vessels were apparently not or less
involved. The different clinical course in PCNSV patients
according to the size of the vessel involved was also shown
by univariate analyses which demonstrated an increased
mortality in patients with large/proximal vessel involvement
compared with the patients with small/distal vessel involvement
(patients with only small/distal vessel involvement at angio-
grams plus patients biopsy positive and angiogram negative).
MacLaren et al51 reported somewhat different results in a series
of 12 patients diagnosed with PCNSV. Six patients grouped as
having midsized vessel involvement (4 had angiograms show-
ing characteristic vasculitis patterns, but no biopsies) responded
to treatment, had an isolated episode and paucity of relapses,
while 6 grouped as small vessel disease (1 case proven by
biopsy) responded to treatment, but had a relapsing course
causing more serious neurologic outcomes. We observed a
correlation only between relapsing disease and the type of
treatment (patients treated with glucocorticoids alone had more
relapses/recurrences). There were no differences regarding
relapses/recurrences between patients biopsy-proven and angio-
graphy-proven or between patients with distal/small vessel
involvement and those with proximal/large vessel involvement.
Furthermore, the patients with relapsing disease did not have a
final outcome different from that of patients without relapses/
recurrences. Differences in case documentation and selection
may account for the differences between MacLaren and co-
workers’ results and ours.
The variations in findings and course observed in this
cohort confirm our previous observations that PCNSV is a
heterogeneous condition composed of >1 entity with differ-
ences in terms of clinical presentations, outcomes and response
to treatment.53 As noted, the size of the vessels involved in the
inflammatory process seems to be responsible for many of these
different clinical characteristics. Rapidly progressive PCNSV
(exemplified by our Case 1) patients characterized by the
angiographic presence of bilateral, multiple, large vessel lesions
and MRI evidence of multiple cerebral infarctions often have
fatal outcomes and represent the worst end of the clinical
spectrum of PCNSV,32,33 while angiography-negative patients
with the involvement of small cortical and leptomeningeal
vessels characterized by a cognitive disorder at presentation
and MRI evidence of prominent leptomeningeal enhancement
(Case 3) have a more benign disease that responds favorably to
treatment.35,36
Calabrese et al initially suggested that most cases defined
only by angiography may represent a more benign form of
PCNSV (benign angiopathy of the CNS or BACNS).16,49 Later,
the same authors concluded that some of these patients did not
have vasculitis and in 2007 they used the term RCVS to identify
various disorders characterized by cerebrovascular spasm,
including also the patients with BACNS.17 In our study, we
made special efforts to exclude patients with RCVS. The fact
that our patients diagnosed by angiography, differently from
Calabrese et al initial observations,16,49 tended to have a pro-
gressive course with a higher mortality supports our view that
they had characteristics of vasculitis rather than vasoconstriction.
Also the histopathological pattern may be a marker of a
distinct condition. As observed in our Case 2, necrotizing
vasculitis was significantly more frequent in patients with
intracranial hemorrhage.28 Overall, necrotizing vasculitis was
a less frequently seen pattern, being present in only 17% of the
patients with histological diagnosis. In these patients, the
histologic appearance of the brain biopsy specimen resembles
the pattern seen in polyarteritis nodosa. The destructive trans-
mural vasculitic process with fibrinoid necrosis may cause
severe vessel wall weakening, thus predisposing to blood vessel
ruptures. Furthermore, a predominant granulomatous and/or
necrotizing pattern characterizes patients with rapidly pro-
gressive course, little response to therapy, and frequent fatal
outcome,32,33 while lymphocytic vasculitis, the only histopatho-
logical pattern observed in children primary angiitis of the
CNS,13 seems to define in the adult a subset with a more benign
vasculitis. None of our patients with lymphocytic vasculitis had
at last follow-up a bad outcome or died. b-Amyloid peptide
deposition in biopsies was found almost exclusively in those
specimens with a granulomatous histologic pattern. Scolding
et al38 suggested that b-amyloid peptide related PCNSV is a
recognizable clinicopathological entity which they refer to as
ABRA. Our Case 4 represents an example of ABRA. As we and
other authors demonstrated, ABRA represents a definable sub-
set of PCNSV characterized by older age at diagnosis, high
frequency of cognitive dysfunction and seizures/spells at pres-
entation, increased spinal fluid protein levels, high frequency of
enhancing leptomeningeal lesions, and favorable response to
glucocorticoids alone or in combination with cyclophospha-
mide.29,38 Cerebral angiography is often negative in patients
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with ABRA (it was positive only in 2 of the 14 patients who had
angiography) and cerebral biopsy is required for the diagnosis.
In ABRA, the inflammation is mainly restricted to the small
cortical and leptomeningeal vessels. Some patients have an
inflammatory nonvasculitic condition related to vascular depo-
sition of b-amyloid peptide with clinical characteristics similar
to ABRA (as exemplified by Case 5) and good treatment
response. These patients are pathologically characterized by a
perivascular nondestructive inflammatory infiltration and this
condition is defined CAA-RI.29,39,40 It is possible that CAA-RI
and ABRA are part of the same pathologic spectrum. Although
CAA-RI patients were not included in our cohort of patients with
PCNSV, this condition appears related toABRAand the clinician
must be aware of the whole spectrum of amyloid-b associated
inflammation. Furthermore, in some cases the pathological dis-
tinction between ABRA and CAA-RI may be difficult.26
We compared the results from the old 1983 to 2003 cohort
to those from the more recent 2004 to 2012 cohort to evaluate
changes in demographic, clinical manifestations, diagnostic
investigations, and outcomes. The age at diagnosis was higher
in the new cohort of patients; however, the clinical manifes-
tations at diagnosis in the 2 cohorts did not change. The higher
frequency of patients with MRA examination at diagnosis in the
more recent cohort reflected the increased use of this technique
for PCNSV diagnosis. The new cohort of patients also had a
more severe disease as pointed out by the higher level of
disability at diagnosis and at last follow-up, notwithstanding
the higher frequency of patients with meningeal enhancement
and the reduced frequency of patients with large vessel disease,
characteristics associated to a more benign disease. Differences
in the treatment between the 2 groups are described in more
detail elsewhere.30
The patients treated with cyclophosphamide and predni-
sone had a higher frequency of persistent neurologic deficit or
stroke and MRI evidence of infarcts at diagnosis compared with
those treated with prednisone alone. Therefore, the therapeutic
choice of adding cyclophosphamide to prednisone at diagnosis
reflected the presence of a more severe disease as also evi-
denced by the higher disability scores at presentation observed
in the patients treated with cyclophosphamide and prednisone.
However, a favorable response was observed in most of the
patients to glucocorticoids alone and glucocorticoids in con-
junction with cyclophosphamide. About 83% of the patients
responded to the treatments, and the response rate was similar in
the 2 treatment groups. This is encouraging for the management
of these patients and emphasizes the need for early recognition
in order to avoid irreversible CNS events. No differences in
outcomes (disability and mortality) were observed in the 2
treatment groups, the only difference regarded the disease
flares. Treatment with prednisone alone was associated with
more frequent relapses. Treatment is described in more detail
elsewhere.30
FIGURE 4. Suggested treatment algorithm for primary central nervous system vasculitis (PCNSV).
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There are no standardized treatment protocols or random-
ized clinical trial evidence to guide therapy. A suggested
treatment algorithm for PCNSV according to our experience
and the data from the literature is shown in Figure 4. We
recommend an initial dose of prednisone of 1mg/kg/d (or
equivalent) in patients with inflammation restricted to small
cortical and leptomeningeal vessels who have a more benign
disease and usually respond favorably to glucocorticoid treat-
ment. If a patient does not respond promptly, cyclophosphamide
should be started. Oral cyclophosphamide or intravenous pulses
that have proved effective in other vasculitides can be
used.4,15,19 An option would be to replace cyclophosphamide
with azathioprine or mycophenolate mofetil that are less toxic
drugs. However, we have not considered this option in our
algorithm because insufficient evidence exists for the effec-
tiveness of these 2 drugs for the induction of remission. In
patients with more severe large/proximal vessel disease and in
those with rapidly progressive course, high-dose intravenous
methylprednisolone (1000mg daily for 3–5 d) and cyclopho-
sphamide can be used to induce remission immediately after
diagnosis. Subsequently, we suggest the use of a low-risk
immunosuppressant such as azathioprine or mycophenolate
mofetil for the maintenance of remission. Evaluating our cohort
of patients with PCNSV, we observed a favorable response to
these 2 drugs and a treatment course of 12 to 18 months was
adequate in most patients.30,31 Methotrexate was used in few of
our patients and in literature; therefore this drug was not
included in the algorithm. Tumor necrosis factor-a blockers
or rituximab may be used in the patients who are intolerant or
respond poorly to cyclophosphamide.54–56
We estimated the survival rate of our patients using the
Kaplan–Meier method, comparing the outcome to the life
expectancy of the US white population. As seen in Figure 2,
the mortality rate was significantly increased in patients with
PCNSV.Themajority of the causes of death thatwere ascertained
were related to neurovascular problems and presumably con-
nected to the PCNSV. Increased mortality rates and high dis-
ability scores at last follow-up were specifically associated with
characteristics associated to the size of the vessel involved. The
presence of cerebral infarctions onMRI, largevessel involvement
on angiograms, and diagnosis by angiography compared with
diagnosis by biopsy reflect the development of more serious and
widespread neurologic lesions correlated with the involvement
of the larger cerebral vessels. Gadolinium-enhanced lesions and
CAA characterize a vasculitic process that involves the smaller
cortical and leptomeningeal vessels and a more benign course.
A strength of this study is the large number of unselected
cases which should provide a more reliable perspective of the
spectrum of clinical findings of PCNSV than the previous
smaller series. The diagnostic exclusion of biopsies that lacked
clear histologic features of vasculitis and angiograms with
single or focal areas of vessel involvement likely eliminated
at least some cases with non-vasculitis conditions. The longer
period of follow-up helped confirm the diagnosis of included
cases, provided time to assess response to treatment, and out-
comes. We were particularly careful to try to exclude cases with
findings of RCVS. The overall clinical characteristics and
disease course of all patients diagnosed with only angiography
were more consistent of an underlying vasculitic process, rather
than the vasoconstriction syndrome.
The study has a number of limitations. Retrospective studies
as this are associated with missing data which may influence the
results. Other limitations include possible referral bias of cases
and lack of tissue at diagnosis in the majority of patients.
In conclusion, our findings indicate that PCNSV is a
heterogeneous condition. Presenting clinical manifestations,
MRI findings, and histopathological patterns may identify
separate disease subsets. However, in our enlarged cohort,
distinct subtypes of PCNSV appeared primarily related to the
size of the vessel involved. The involvement of small cortical/
leptomeningeal vessel was associated with a more benign
disease course, while the involvement of larger/proximal
cerebral vessels characterized patients with a less favorable
prognosis who should be treated more aggressively. We also
confirmed that PCNSV is associated with an increased morbid-
ity and mortality, but also with high rates of favorable response
to glucocorticoids alone or with cyclophosphamide. An early
recognition and treatment of this vasculitis will help avoid
serious outcomes.
REFERENCES
1. Harbitz F. Unknown forms of arteritis, with special reference to their
relation to syphilitic arteritis and periarteritis nodosa. Am J Med Sci.
1922;163:250–272.
2. Newman W, Wolf A. Non-infectious granulomatous angiitis invol-
ving the central nervous system. Trans Am Neurol Assoc.
1952;77:114–117.
3. McCormick HM, Neubuerger KT. Giant-cell arteritis involving small
meningeal and intracerebral vessels. J Neuropathol Exp Neurol.
1958;17:471–478.
4. Cupps TR, Moore PM, Fauci AS. Isolated angiitis of the central
nervous system. Prospective diagnostic and therapeutic experience.
Am J Med. 1983;74:97–105.
5. Calabrese LH, Mallek JA. Primary angiitis of the central nervous
system. Report of 8 new cases, review of the literature, and proposal
for diagnostic criteria. Medicine (Baltimore). 1988;67:20–39.
6. Cravioto H, Feigin I. Noninfectious granulomatous angiitis with a
predilection for the nervous system. Neurology. 1959;9:599–609.
7. Lie JT. Primary (granulomatous) angiitis of the central nervous
system: a clinicopathologic analysis of 15 new cases and a review of
the literature. Human Pathol. 1992;23:164–171.
8. Sandhu R, Alexander S, Hornabrook RW, et al. Granulomatous
angiitis of the CNS. Arch Neurol. 1979;36:433–435.
9. Alrawi A, Trobe JD, Blaivas M, et al. Brain biopsy in primary
angiitis of the central nervous system. Neurology. 1999;53:858–860.
10. Moore PM. Diagnosis and management of isolated angiitis of the
central nervous system. Neurology. 1989;39:167–173.
11. Salvarani C, Brown RD Jr, Hunder GG. Adult primary central
nervous system vasculitis. Lancet. 2012;380:767–777.
12. Birnbaum J, Hellmann DB. Primary angiitis of the central nervous
system. Arch Neurol. 2009;66:704–709.
13. Hajj-Ali RA, Singhal AB, Benseler S, et al. Primary angiitis of the
CNS. Lancet Neurol. 2011;10:561–572.
14. Kadkhodayan Y, Alreshaid A, Moran CJ, et al. Primary angiitis of
the central nervous system at conventional angiography. Radiology.
2004;233:878–882.
15. Salvarani C, Brown RD Jr, Hunder GG. Adult primary central
nervous system vasculitis: an update. Curr Opin Rheumatol.
2012;24:46–52.
16. Calabrese LH, Gragg LA, Furlan AJ. Benign angiopathy: a distinct
subset of angiographically defined primary angiitis of the central
nervous system. J Rheumatol. 1993;20:2046–2050.
17. Calabrese LH, Dodick DW, Schwedt TJ, et al. Narrative review:
reversible cerebral vasoconstriction syndromes. Ann Intern Med.
2007;146:34–44.
Salvarani et al Medicine  Volume 94, Number 21, May 2015
14 | www.md-journal.com Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
18. Ducros A, Bousser MG. Reversible cerebral vasoconstriction syn-
drome. Pract Neurol. 2009;9:256–267.
19. De Boysson H, Zuber M, Naggara O, et al., French Vasculitis Study
Group and the French NeuroVascular Society. Primary angiitis of
the central nervous system: description of the first fifty-two adults
enrolled in the French cohort of patients with primary vasculitis of
the central nervous system. Arthritis Rheumatol. 2014;66:1315–1326.
20. Oon S, Roberts C, Gorelik A, et al. Primary angiitis of the central
nervous system: experience of a Victorian tertiary-referral hospital.
Intern Med J. 2013;43:685–692.
21. Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central
nervous system vasculitis: analysis of 101 patients. Ann Neurol.
2007;62:442–451.
22. von Elm E, Altman DG, Egger M, et al., STROBE Initiative. The
Strengthening the Reporting of Observational Studies in Epidemiol-
ogy (STROBE) statement: guidelines for reporting observational
studies. Ann Intern Med. 2007;147:573–577.
23. Sulter G, Steen C, DeKeyser J. Use of the Barthel index and
modified Rankin scale in acute stroke trials. Stroke. 1999;30:1538–
1541.
24. Hakulinen T. Cancer survival corrected for heterogeneity in patient
withdrawal. Biometrics. 1982;38:933–942.
25. Maradit Kremers H, Crowson CS, Gabriel SE. Rochester Epidemiol-
ogy Project: a unique resource for research in the rheumatic diseases.
Rheum Dis Clin North Am. 2004;30:819–834.
26. Giannini C, Salvarani C, Hunder G, et al. Primary central nervous
system vasculitis: pathology and mechanisms. Acta Neuropathol.
2012;123:759–772.
27. Miller DV, Salvarani C, Hunder GG, et al. Biopsy findings in
primary angiitis of the central nervous system. Am J Surg Pathol.
2009;33:35–43.
28. Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central
nervous system vasculitis presenting with intracranial hemorrhage.
Arthritis Rheum. 2011;63:3598–3606.
29. Salvarani C, Hunder GG, Morris JM, et al. Ab-related angiitis:
comparison with CAA without inflammation and primary CNS
vasculitis. Neurology. 2013;81:1596–1603.
30. Salvarani C, Brown RD Jr, Christianson TJH, Huston J 3rd, Giannini
C, Miller DV, Hunder GG. Adult primary central nervous system
vasculitis treatment and course: analysis of 163 patients. Arthritis
Rheumatol 2015. doi: 10.1002/act.39068 [Epub ahead of print].
31. Salvarani C, Brown RD Jr, Christianson TJH, Huston J 3rd, Giannini
C, Miller DV, Muratore F, Hunder GG. Mycophenolate mofetil in
primary central nervous system vasculitis. Semin Arthritis Rheum .
2015. doi: 10.1016/j.semarthrit.2015.02.008 [Epub ahead of print].
32. Salvarani C, Brown RD Jr, Calamia KT, et al. Rapidly progressive
primary central nervous system vasculitis. Rheumatology (Oxford).
2011;50:349–358.
33. Salvarani C, Brown RD Jr, Morris JM, et al. Catastrophic primary
central nervous system vasculitis. Clin Exp Rheumatol.
2014;32(Suppl 82):S3–S4.
34. Salvarani C, Brown RD Jr, Calamia KT, et al. Primary CNS
vasculitis with spinal cord involvement. Neurology. 2008;70:2394–
2400.
35. Salvarani C, Brown RD Jr, Calamia KT, et al. Angiography-
negative primary central nervous system vasculitis: a syndrome
involving small cerebral vessels. Medicine (Baltimore).
2008;87:264–271.
36. Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central
nervous system vasculitis with prominent leptomeningeal enhance-
ment: a subset with a benign outcome. Arthritis Rheum.
2008;58:595–603.
37. Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central
nervous system vasculitis: comparison of patients with and without
cerebral amyloid angiopathy. Rheumatology (Oxford). 2008;47:1671–
1677.
38. Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis:
primary angiitis of the central nervous system associated with
cerebral amyloid angiopathy. Brain. 2005;128:500–515.
39. Eng JA, Frosch MP, Choi K, et al. Clinical manifestations of
cerebral amyloid angiopathy-related inflammation. Ann Neurol.
2004;55:250–256.
40. Kinnecom C, Lev MH, Wendell L, et al. Course of cerebral amyloid
angiopathy-related inflammation. Neurology. 2007;68:1411–1416.
41. Alhalabi M, Moore PM. Serial angiography in isolated angiitis of
the central nervous system. Neurology. 1994;44:1221–1226.
42. Calabrese LH. Primary angiitis of the central nervous system: the
penumbra of vasculitis. J Rheumatol. 2001;28:245–246.
43. Duna GF, Calabrese LH. Limitations of invasive modalities in the
diagnosis of primary angiitis of the central nervous system.
J Rheumatol. 1995;22:662–667.
44. Lie JT. Angiitis of the central nervous system. Curr Opinion
Rheumatol. 1991;3:36–45.
45. Moore PM. Vasculitis of the central nervous system. Curr Rheuma-
tol Rep. 2000;2:376–382.
46. Younger DS. Vasculitis of the nervous system. Curr Opinion Neurol.
2004;17:317–336.
47. Moore PM. Central nervous system vasculitis. Curr Opinion Neurol.
1998;11:241–246.
48. Zuccoli G, Pipitone N, Haldipur A, et al. Imaging findings in
primary central nervous system vasculitis. Clin Exp Rheumatol.
2011;29(Suppl 64):S104–S109.
49. Hajj-Ali RA, Furlan A, Abou-Chebel A, et al. Benign angiopathy of
the central nervous system: cohort of 16 patients with clinical course
and long-term followup. Arthritis Rheum. 2002;47:662–669.
50. Hellmann DB, Roubenoff R, Healy RA, et al. Cenral nervous system
angiography: safety and predictors of a positive result in 125
consecutive patients evaluated for possible vasculitis. J Rheumatol.
1992;19:568–572.
51. MacLaren K, Gillespie J, Shrestha S, et al. Primary angiitis of the
central nervous system: emerging variants. Q J Med. 2005;98:643–
654.
52. Woolfenden AR, Tong DC, Marks MP, et al. Angiographically
defined primary angiitis of the CNS. Neurology. 1998;51:183–188.
53. Hunder GG, Salvarani C, Brown RD Jr. Primary central nervous
system vasculitis: is it a single disease? Ann Neurol. 2010;68:573–
574.
54. De Boysson H, Arquizan C, Guillevin L, et al. Rituximab for
primary angiitis of the central nervous system: report of 2 patients
from the French COVAC cohort and review of the literature.
J Rheumatol. 2013;40:2102–2103.
55. Salvarani C, Brown RD Jr, Calamia KT, et al. Efficacy of tumor
necrosis factor alpha blockade in primary central nervous system
vasculitis resistant to immunosuppressive treatment. Arthritis Rheum.
2008;59:291–296.
56. Salvarani C, Brown RD Jr, Huston J 3rd et al. Treatment of
primary central nervous system vasculitis with rituximab: case
report. Neurology. 2014;82:1287–1288.
Medicine  Volume 94, Number 21, May 2015 Analysis of Patients With PCNSV
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved. www.md-journal.com | 15
